Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Canadian Myeloma Research Group
Massachusetts General Hospital
University of California, San Francisco
Masonic Cancer Center, University of Minnesota
Augusta University
Massachusetts General Hospital
University of Miami
Washington University School of Medicine
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
University of California, San Francisco
Peking University People's Hospital
Peking University People's Hospital
Memorial Sloan Kettering Cancer Center
Brigham and Women's Hospital
Fred Hutchinson Cancer Center
Memorial Sloan Kettering Cancer Center
University of Oklahoma
M.D. Anderson Cancer Center
University College Cork
Cedars-Sinai Medical Center
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Fondazione IRCCS Policlinico San Matteo di Pavia
Centre Hospitalier Henri Duffaut - Avignon
Institute of Hematology & Blood Diseases Hospital, China
Universitaire Ziekenhuizen KU Leuven
Baylor College of Medicine
University of Illinois at Chicago
University of Miami
SCRI Development Innovations, LLC
University of Miami
University of Miami
University of California, San Diego
City of Hope Medical Center
M.D. Anderson Cancer Center
Hackensack Meridian Health
M.D. Anderson Cancer Center
Poitiers University Hospital
Essen Biotech
University of Texas Southwestern Medical Center
University of Utah
American Society of Clinical Oncology
University of Alabama at Birmingham
Institute of Hematology & Blood Diseases Hospital, China
The First Hospital of Jilin University
Fundación Española de Hematología y Hemoterapía
Memorial Sloan Kettering Cancer Center
Emory University